Definitive Contract HHSO100201700020C

Award Date 9/21/17
Potential Completion Date 9/24/27
Potential Value $692M
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Sharing
Place of Performance
Sleepy Hollow, NY 10591, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed

This is a federal contract award to Regeneron Pharmaceuticals Inc., a for-profit manufacturer of pharmaceuticals and therapeutics. The $692,086,314.00 award was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS). The contract is for the development and production of "novel antibodies against influenza virus, emerging, re-emerging, and pre-emerging pathogens" under an Other Transaction Authority (OTA) agreement. The award has a period of performance through September 2027 and does not have a set-aside designation. The contract is a definitive contract with a cost-sharing pricing type. This award appears to be part of a broader effort by the government to develop and maintain a national stockpile of critical medical countermeasures, such as those needed to respond to the COVID-19 pandemic.

Generated 12/6/24, 9:32 AM